{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04151940",
            "orgStudyIdInfo": {
                "id": "RG1005458"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2019-07068",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "10203",
                    "type": "OTHER",
                    "domain": "Fred Hutch/University of Washington Cancer Consortium"
                },
                {
                    "id": "R01CA258997",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA258997"
                }
            ],
            "organization": {
                "fullName": "University of Washington",
                "class": "OTHER"
            },
            "briefTitle": "PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer",
            "officialTitle": "An Interventional Study of PET/CT Changes During Chemoimmunotherapy and Radiation Therapy for Patients With Metastatic NSCLC",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "pet-ct-changes-during-chemoimmunotherapy-and-radiation-therapy-in-patients-with-stage-iv-non-small-cell-lung-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-09-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-10-30",
            "studyFirstSubmitQcDate": "2019-11-01",
            "studyFirstPostDateStruct": {
                "date": "2019-11-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Washington",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer. Analyzing changes in PET/CT imaging scans may help doctors assess and predict patterns of cancer response to chemoimmunotherapy and radiation therapy.",
            "detailedDescription": "Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Lung Non-Small Cell Carcinoma",
                "Recurrent Lung Non-Small Cell Carcinoma",
                "Stage IV Lung Cancer AJCC v8"
            ],
            "keywords": [
                "Lung"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Research (PET/CT scan)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients undergo PET/CT scan within 4 weeks before starting standard of care chemoimmunotherapy and a second PET/CT scan within 5 days of the second chemoimmunotherapy cycle. Patients receiving standard of care radiation treatment undergo additional PET/CT scans within 4 weeks prior to radiation treatment and 1 month post-radiation treatment.",
                    "interventionNames": [
                        "Procedure: Positron Emission Tomography",
                        "Procedure: Computed Tomography",
                        "Drug: Chemotherapy",
                        "Biological: Immunotherapy",
                        "Radiation: Radiation Therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "PROCEDURE",
                    "name": "Positron Emission Tomography",
                    "description": "Undergo PET/CT scan",
                    "armGroupLabels": [
                        "Research (PET/CT scan)"
                    ],
                    "otherNames": [
                        "Medical Imaging",
                        "PET",
                        "PET scan",
                        "positron emission tomography scan",
                        "Positron-Emission Tomography",
                        "proton magnetic resonance spectroscopic imaging"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Computed Tomography",
                    "description": "Undergo PET/CT scan",
                    "armGroupLabels": [
                        "Research (PET/CT scan)"
                    ],
                    "otherNames": [
                        "CAT",
                        "CAT Scan",
                        "computerized axial tomography",
                        "computerized tomography",
                        "CT",
                        "CT SCAN"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Chemotherapy",
                    "description": "Receive standard of care chemotherapy",
                    "armGroupLabels": [
                        "Research (PET/CT scan)"
                    ],
                    "otherNames": [
                        "Chemo",
                        "Chemotherapy (NOS)"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Immunotherapy",
                    "description": "Receive standard of care immunotherapy",
                    "armGroupLabels": [
                        "Research (PET/CT scan)"
                    ],
                    "otherNames": [
                        "Immunological",
                        "Immunological Therapy",
                        "Immunologically Directed Therapy"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Radiation Therapy",
                    "description": "Undergo standard of care radiation therapy",
                    "armGroupLabels": [
                        "Research (PET/CT scan)"
                    ],
                    "otherNames": [
                        "Cancer Radiotherapy",
                        "Irradiate",
                        "irradiated",
                        "Irradiation",
                        "Radiation",
                        "Radiotherapeutics",
                        "radiotherapy",
                        "RT"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-free survival (PFS)",
                    "description": "Will be compared between high-risk and low-risk subgroups of patients based on PET imaging response assessment using a two-sample proportionality test. Interim and final statistical analyses of PFS will consist of Kaplan-Meier estimation and Cox proportional hazard regression.",
                    "timeFrame": "At 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically-confirmed or cytologically-confirmed metastatic NSCLC in patients who have not received chemotherapy or immunotherapy for their advanced disease (stage IV or recurrent, using the American Joint Committee on Cancer \\[AJCC\\]/Union for International Cancer Control \\[UICC\\] 8th edition for staging)\n* Evidence of stage IV disease on imaging by CT, PET/CT, or magnetic resonance imaging (MRI)\n* Plan to treat with a platinum doublet with a PD1 or PDL1 inhibitor\n* Adjuvant chemotherapy or concurrent chemoradiation for early stage disease does not count as prior therapy unless subject progressed within 6 months of completion of regimen.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, at treating physician's discretion\n* Patients with known activating mutations in EGFR, BRAF or known translocation in ALK or ROS-1 are eligible provided they have progressed on or were intolerant to Food and Drug Administration (FDA) approved targeted therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* Creatinine =\\< 2 mg/dL or creatinine clearance \\> 50 mL/min\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 5x institutional upper limit of normal\n* Total bilirubin =\\< 1.5 mg/dL\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9/L (\\>= 1500 per mm\\^3)\n* Platelet count \\>= 100 x 10\\^9/L (\\>=100,000 per mm\\^3)\n* Capability to understand and comply with the protocol requirements and signed informed consent documents\n\nExclusion Criteria:\n\n* Any known additional malignancy (with exception of non-melanoma skin cancer, in-situ breast cancer, low risk prostate cancer, or a malignancy diagnosed \\>= 3 years prior to the current NSCLC diagnosis and with no evidence of requiring active treatment)\n* Had prior treatment with an anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms\n* Has any serious or uncontrolled active infection that could create false positives on a PET/CT scan, in the opinion of the treating investigator\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator\n* Has an active autoimmune disease currently requiring systemic treatment (e.g. disease modifying agents, corticosteroids or immunosuppressive drugs)\n\n  \\*\\*Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment\n* Has known, active, and symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis\n\n  * Patients with stable or previously treated brain metastases are eligible as long as they are not receiving more than 10 mg of prednisone, or equivalent, per day",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rafael Santana-Davila",
                    "role": "CONTACT",
                    "phone": "206.606.2190",
                    "email": "rsantan2@fredhutch.org"
                },
                {
                    "name": "Stephen Bowen",
                    "role": "CONTACT",
                    "phone": "206.543.6559",
                    "email": "srbowen@uw.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rafael Santana-Davila, MD",
                    "affiliation": "Fred Hutch/University of Washington Cancer Consortium",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Fred Hutch/University of Washington Cancer Consortium",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Stephen R. Bowen, PhD",
                            "role": "CONTACT",
                            "phone": "206-543-6559",
                            "email": "srbowen@uw.edu"
                        },
                        {
                            "name": "Stephen R. Bowen, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Jing Zeng, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Rafael Santana-Davila, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Lung Non-Small Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000091369",
                    "term": "Immunomodulating Agents"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "asFound": "Modules",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}